Myelofibrosis and Systemic Mastocytosis — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Research To Practice | Oncology Videos
Featuring perspectives from Prof Claire Harrison, Dr Andrew T Kuykendall, Dr Stephen T Oh, Dr Jeanne Palmer and Dr Raajit K Rampal, including the following topics: Introduction (0:00) Current Clinical Decision-Making for Myelofibrosis (MF) in the Absence of Severe Cytopenias — Dr Palmer (1:46) Case: A woman in her mid 70s presents with symptomatic JAK2 V61F-mutant primary MF with mild anemia and normal platelet count — John Mascarenhas, MD (16:09) Discussion: Asymptomatic MF; re-reads of pathology reports; “triple-negative” MF; secondary causes — Laura C Michaelis, MD (22:47)...
info_outline
Antibody-Drug Conjugates for Breast Cancer — Proceedings from a San Antonio 2025 Symposium Series
Research To Practice | Oncology Videos
Featuring perspectives from Dr Javier Cortés, Dr Rita Nanda, Prof Peter Schmid and Dr Priyanka Sharma, including the following topics: Introduction (0:00) Case: A woman in her early 80s with multiple comorbidities and triple-negative breast cancer (TNBC) develops bone-only metastases 4 months after declining capecitabine for post-neoadjuvant residual disease — Justin Favaro, MD, PhD (1:50) Case: A woman in her mid 70s with ER-negative, HER2-low (IHC 1+), PIK3CA-mutated, PD-L1-positive metastatic breast cancer (mBC) after receiving 3 cycles of neoadjuvant...
info_outline
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Research To Practice | Oncology Videos
Featuring perspectives from Dr Matthew S Davids, Dr Bita Fakhri, Prof Constantine Tam and Dr Jennifer Woyach, including the following topics: Introduction (0:00) Current and Emerging Approaches to First-Line Therapy for Chronic Lymphocytic Leukemia (CLL) — Dr Davids (1:42) Case: A man in his mid 70s with a plethora of comorbidities but good performance status requires treatment for CLL — Bhavana (Tina) Bhatnagar, DO (14:58) Case: A man in his early 50s, a Jehovah’s Witness, under observation for IGHV-mutated CLL develops pulmonary emboli and worsening lymphadenopathy, undergoes...
info_outline
Colorectal Cancer — 5-Minute Journal Club Issue 1 with Dr Scott Kopetz: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays
Research To Practice | Oncology Videos
Featuring an interview with Dr Scott Kopetz, including the following topics: Circulating tumor DNA (ctDNA)-based molecular residual disease (MRD) and survival among patients with resectable colorectal cancer (CRC) in the CIRCULATE-Japan GALAXY trial (0:00) ctDNA for detection of MRD in patients with CRC in the BESPOKE CRC and INTERCEPT trials (3:11) Clinical utility of including ctDNA monitoring in standard CRC surveillance (11:11) ctDNA analysis guiding adjuvant therapy for CRC in the DYNAMIC and CIRCULATE-North America trials (15:52)
info_outline
Acute Myeloid Leukemia — Proceedings from a Symposium Series Preceding the 67th ASH Annual Meeting and Exposition
Research To Practice | Oncology Videos
Featuring perspectives from Dr Harry Paul Erba, Dr Amir Fathi, Dr Tara L Lin, Dr Alexander Perl and Dr Eytan M Stein, including the following topics: Introduction (0:00) Up-Front Therapy for Older Patients with Acute Myeloid Leukemia (AML) — Dr Lin (1:46) Selection of Therapy for Younger Patients with AML without a Targetable Mutation; Promising Investigational Strategies — Dr Perl (25:38) Role of FLT3 Inhibitors in AML Management — Dr Erba (48:27) Incorporation of IDH Inhibitors into the Care of Patients with AML — Dr Fathi (1:10:28) Current and Future Role of Menin Inhibitors...
info_outline
Toxicities Associated with Antibody-Drug Conjugates for Metastatic Breast Cancer — Clinical Investigator Perspectives on Actual Patient Cases
Research To Practice | Oncology Videos
Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics: Overview: Molecular basis of antibody-drug conjugate (ADC) toxicities — Sequencing of ADCs and mechanisms of resistance (0:00) Case: A woman in her late 60s with localized triple-negative breast cancer develops myocarditis during neoadjuvant therapy with chemotherapy/pembrolizumab — Richard Zelkowitz, MD (8:22) Case: A woman in her mid 70s with recurrent ER-negative, HER2-low, PD-L1-positive metastatic breast cancer (mBC) who experiences disease progression on nab paclitaxel/atezolizumab...
info_outline
Advanced Gastroesophageal Cancers — Expert Perspectives on Actual Patient Cases: Part 2 of 2
Research To Practice | Oncology Videos
Featuring perspectives from Dr Yelena Y Janjigian, including the following topics: Introduction (0:00) Case: A man in his early 60s with a history of Barrett's esophagus presents with HER2-positive metastatic esophageal adenocarcinoma and a PD-L1 combined positive score (CPS) of 3 — Jennifer Yannucci, MD (10:20) Case: A man in his early 60s with multiregimen-recurrent HER2-positive gastroesophageal junction (GEJ) adenocarcinoma (claudin 18.2-positive, PD-L1 CPS 0) — Neil Morganstein, MD (14:53) Case: A woman in her early 80s with dementia and newly diagnosed mismatch repair-deficient,...
info_outline
Urothelial Bladder Cancer and Prostate Cancer — Highlights from the 2025 ESMO Annual Meeting
Research To Practice | Oncology Videos
Featuring perspectives from Dr Terence Friedlander and Dr Rana R McKay, including the following topics: Introduction (0:00) Prostate Cancer (1:44) Urothelial Bladder Cancer (29:18)
info_outline
Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy
Research To Practice | Oncology Videos
Featuring perspectives from Dr Luis Paz-Ares and Dr Misty Dawn Shields, including the following topics: Introduction: Tail on the Curve? (0:00) First-Line Chemoimmunotherapy (10:45) Maintenance Lurbinectedin (28:42) Second-Line Treatment, Tarlatamab (45:35) Ongoing Research (53:20)
info_outline
Gastroesophageal Cancers — Proceedings from a Symposium Held in Partnership with the American Oncology Network
Research To Practice | Oncology Videos
Featuring perspectives from Dr Manish A Shah, moderated by Dr Stephen “Fred” Divers, including the following topics: Highlights and Principles of Management of Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma — Dr Shah (0:00) Case: A man in his early 50s with microsatellite instability-high localized esophageal adenocarcinoma — Dr Mulherin (15:24) Case: A woman in her late 60s with HER2-positive (IHC 3+) and HER2 TKD-mutant metastatic esophageal adenocarcinoma — Dr Warsch (25:34) Case: A woman in her early 70s with HER2-positive (IHC 3+), PD-L1-negative,...
info_outlineFeaturing slide presentations and related discussion from Prof Francois-Clement Bidard, Dr Hope S Rugo, Dr Rebecca Shatsky and Dr Seth Wander, including the following topics:
- Optimal approach to biomarker testing for patients with ER-positive metastatic breast cancer (mBC) (0:00)
- Case: A woman in her early 70s with recurrent ER-positive, HER2-negative mBC receives elacestrant (15:15)
- Case: A woman in her early 60s with ER-positive, HER2-low, PIK3CA-mutated mBC receives inavolisib-based therapy and experiences no disease progression for 24 months (18:02)
- Role of oral selective estrogen receptor degrader (SERD) monotherapy in the treatment of progressive ER-positive, HER2-negative mBC (26:26)
- Case: A woman in her mid 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (44:12)
- Case: A woman in her early 50s with recurrent HR-positive, HER2-negative, PIK3CA-mutant mBC receives capivasertib and fulvestrant (45:33)
- Potential novel applications of oral SERDs in the management of ER-positive, HER2-negative breast cancer (51:25)
- Case: A woman in her mid 50s with recurrent ER-positive, HER2-negative, PIK3CA-mutated mBC experiences disease progression 18 months after starting first-line letrozole and ribociclib (1:03:46)
- Case: A woman in her mid 50s with ER-positive, HER2-negative breast cancer undergoes serial ctDNA monitoring during first-line therapy (1:06:54)
- Tolerability and other practical considerations with oral SERDs (1:14:30)
- Case: A woman in her early 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (1:33:26)
- Case: A woman in her early 60s with recurrent HR-positive, HER2-negative mBC receives elacestrant (1:37:38)